PALI

PALISADE BIO, INC. PALI

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.7M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$500.0K

Quarter to Jun 30

Net income

$-10.57M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$362.41M total
Soleus Capital Management, L.P.
$27.30MNew
B Group, Inc.
$23.86M0.0%
AMERIPRISE FINANCIAL INC
$23.16M+27.2%
Jupiter Topco LLC
$22.39M--
BlackRock, Inc.
$21.81M+456.2%
Octagon Capital Advisors LP
$21.48M0.0%
PERCEPTIVE ADVISORS LLC
$17.61M-5.6%
RA CAPITAL MANAGEMENT, L.P.
$14.89M0.0%
FRANKLIN RESOURCES INC
$12.09M0.0%
Point72 Asset Management, L.P.
$10.98M+1175.8%
Boxer Capital Management, LLC
$10.03M0.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$9.40M0.0%
Eversept Partners, LP
$8.74M-16.1%
GEODE CAPITAL MANAGEMENT, LLC
$7.86M+143.2%
WELLINGTON MANAGEMENT GROUP LLP
$7.74M+27.5%
GOLDMAN SACHS GROUP INC
$7.48M-33.4%
FEDERATED HERMES, INC.
$6.56M0.0%
Squadron Capital Management LLC
$6.27M0.0%
Propel Bio Management, LLC
$5.40M+131.6%
Vestal Point Capital, LP
$5.22M0.0%
STATE STREET CORP
$5.17M+289.1%
MORGAN STANLEY
$5.17M-45.6%
ORBIMED ADVISORS LLC
$4.88M0.0%
GREAT POINT PARTNERS LLC
$4.78M-32.9%
SPHERA FUNDS MANAGEMENT LTD.
$4.72M+30.2%
See all 124 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/PALI

Earnings Per Share

13fpro.ai/company/PALI

Loading ratio trend…

PALI key financials by period

Reported revenue, net income and operating margin by fiscal year, from PALISADE BIO, INC.'s annual filings on SEC EDGAR.

PALISADE BIO, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2023$250.0K$-12.3M—
FY 2020$13.5K$-10.3M—
FY 2019$15.4K$-8.4M—
FY 2018$260.0K$-4.9M—
FY 2017$260.0K$-15.7M—
FY 2016$16.2K$-21.1M—
Source: PALI filings on SEC EDGAR →

PALI insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About PALISADE BIO, INC. (PALI): stock profile, AI score and financials

PALISADE BIO, INC. (PALI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PALI is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.7m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), PALISADE BIO, INC. reports quarterly revenue of $500.0K, net income of $-10.6M. Top institutional holders of PALI by reported 13-F value include Soleus Capital Management, L.P., B Group, AMERIPRISE FINANCIAL, based on the most recent SEC filings. PALI trades on the Nasdaq exchange and files with the SEC under CIK 1357459. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PALI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PALISADE BIO, INC. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1357459 →